Caribou Biosciences (CRBU) Total Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Liabilities data on file, last reported at $47.0 million in Q1 2026.

• Quarterly Total Liabilities fell 16.75% year-over-year to $47.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (down 16.75% YoY) and the FY2025 annual result came in at $53.2 million, down 11.88% from the prior year.
• Total Liabilities declined to $47.0 million in Q1 2026 per CRBU's latest filing, from $53.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $80.2 million in Q2 2023 and bottomed at $47.0 million in Q1 2026.
• The 5-year median for Total Liabilities is $63.1 million (2024), against an average of $63.6 million.
• The widest annual swing landed in 2022, when Total Liabilities surged 107.91%; it then slipped 22.09% in 2024.
• Tracing CRBU's Total Liabilities over 5 years: stood at $72.9 million in 2022, then dropped by 12.46% to $63.8 million in 2023, then retreated by 5.4% to $60.4 million in 2024, then dropped by 11.88% to $53.2 million in 2025, then decreased by 11.68% to $47.0 million in 2026.
• Per Business Quant, the three latest CRBU Total Liabilities figures stand at $47.0 million (Q1 2026), $53.2 million (Q4 2025), and $53.1 million (Q3 2025).

Peer Comparison